Eylea HD
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Eylea HD in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Eylea HD.
39
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Eylea HD
And firm looks for turnaround in 2017 from Stivarga
Institute says ‘gaps and uncertainties’ in the treatment’s evidence directed its decision
Comes after the Institute effectively shut down for the General Election
Says drug provides no additional benefit over Novartis’ rival Lucentis in eye condition
Bayer’s medicine recommended for NHS use to treat wet AMD
German HTA body unhappy with Lucentis comparison data and turns down Bayer-Regeneron wet AMD drug
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology